AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7433476 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.025%) ophthalmic solution, 2 drops 4 times daily
Number of subjects: 100
Study 7433476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31651367 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic case formulations made by experienced clinicians using simple experience-near language
Number of subjects: 0
Study 31651367 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferred mechanisms component of the formulations
Number of subjects: 0
Study 29698983 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (supervised thrice-weekly for 16 weeks)
Number of subjects: 24
Study 29698983 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 27504699 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 week exercise-based fall prevention program including muscle strengthening and challenging balance training exercises, combined with a 12 week home-based exercise program
Number of subjects: 378
Study 27504699 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 378
Study 24505281 — intervention group
Group type: EXPERIMENTAL
Intervention: TSAT ≤20%
Number of subjects: 879
Study 24505281 — intervention group
Group type: COMPARATOR
Intervention: TSAT 20-40%
Number of subjects: 879
Study 22412976 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light-filtering IOLs
Number of subjects: 1690
Study 20172547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac and acetaminophen
Number of subjects: 55
Study 20172547 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 55
Study 17954515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol plus promethazine
Number of subjects: 316
Study 17954515 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol alone
Number of subjects: 316
Study 16292955 — intervention group
Group type: EXPERIMENTAL
Intervention: Macro-optical digital bronchoscopes with image analysis
Number of subjects: 0
Study 16292955 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time airway color analysis imaging system
Number of subjects: 0
Study 16292955 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D structure extraction from 2-D bronchoscope images using MDCT
Number of subjects: 0
Study 12829647 — intervention group
Group type: EXPERIMENTAL
Intervention: NN2211 (7.5 micro g/kg)
Number of subjects: 10
Study 12829647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9892294 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment program (25 hours/week, 12 weeks duration)
Number of subjects: 291
Study 9892294 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (standard methadone maintenance plus weekly skills training group, 12 weeks duration)
Number of subjects: 291
Study 9892294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (day treatment and enhanced standard care)
Number of subjects: 291
Study 7634948 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 103
Study 2197314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 72
Study 7027923 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination using nalidixic acid, co‐trimoxazole, or polymyxin for gram-negative rods; amphotericin B or nystatin for yeasts.
Number of subjects: 0
Study 7027923 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment was used).
Number of subjects: 0
Study 31468473 — intervention group
Group type: EXPERIMENTAL
Intervention: maraviroc-containing ART
Number of subjects: 233
Study 31468473 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir-containing ART
Number of subjects: 233
Study 31290996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg orally twice daily) plus Bevacizumab (10 mg/kg intravenously on day 1 of each 14-day cycle)
Number of subjects: 121
Study 31290996 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab (10 mg/kg intravenously on day 1 of each 14-day cycle)
Number of subjects: 121
Study 31290996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus Bevacizumab
Number of subjects: 121
Study 31290996 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Bevacizumab
Number of subjects: 121
Study 28650857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study 28650857 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) and Physical Therapy
Number of subjects: 0
Study 28650857 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and Physical Therapy
Number of subjects: 0
Study 27737842 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin for prevention of COPD exacerbations
Number of subjects: 1107
Study 25274861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary uridine triphosphate (UTP)
Number of subjects: 25
Study 25274861 — intervention group
Group type: COMPARATOR
Intervention: Intravenous adenosine (IV adenosine)
Number of subjects: 25
Study 25274861 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary adenosine (IC adenosine)
Number of subjects: 25
Study 22209181 — intervention group
Group type: EXPERIMENTAL
Intervention: 8mg dexamethasone intramuscular injection 1 hour preoperatively
Number of subjects: 20
Study 22209181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 20
Study 19303940 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 81
Study 19303940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 17229423 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 40 minutes
Number of subjects: 0
Study 15179345 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional anesthesia plus isoflurane (ISO)
Number of subjects: 60
Study 15179345 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional anesthesia after shifting to insulin (I‐CA)
Number of subjects: 60
Study 15179345 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional anesthesia plus isoflurane after shifting to insulin (I‐ISO)
Number of subjects: 60
Study 15179345 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia (CA)
Number of subjects: 60
Study 15179345 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia (G‐CA)
Number of subjects: 60
Study 15179345 — intervention group
Group type: COMPARATOR
Intervention: Conventional anesthesia plus isoflurane (G‐ISO)
Number of subjects: 60
Study 12324494 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(12) (0.4 mg), folic acid (0.8 mg), and vitamin B(6) (40 mg)
Number of subjects: 88
Study 12324494 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(12) and folic acid
Number of subjects: 88
Study 12324494 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6)
Number of subjects: 88
Study 12324494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 9637646 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (20 microg/h)
Number of subjects: 54
Study 9637646 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline-intravenous fentanyl (20 microg/h)
Number of subjects: 54
Study 9637646 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline-intravenous saline (control)
Number of subjects: 54
Study 9637646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (20 microg/h)
Number of subjects: 54
Study 8059869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory integration program (3 sessions of 45 minutes per week for 10 weeks)
Number of subjects: 40
Study 8059869 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 3189722 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beclomethasone dipropionate 100 micrograms in each nostril twice daily for 4 weeks
Number of subjects: 30
Study 3189722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3189722 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprospan (betamethasone dipropionate 5 mg and betamethasone disodium phosphate 2 mg per ml) injection
Number of subjects: 30
Study 31673708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic radiosurgery (NaSRS)
Number of subjects: 30
Study 29703575 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement during the 6-minute walk test
Number of subjects: 148
Study 29703575 — intervention group
Group type: COMPARATOR
Intervention: No encouragement during the 6-minute walk test
Number of subjects: 148
Study 27586678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus- and probucol-eluting stent
Number of subjects: 870
Study 27586678 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent
Number of subjects: 870
Study 24815326 — intervention group
Group type: EXPERIMENTAL
Intervention: Aramchol 300 mg/day
Number of subjects: 60
Study 24815326 — intervention group
Group type: EXPERIMENTAL
Intervention: Aramchol 100 mg/day
Number of subjects: 60
Study 24815326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22349644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (behavior change around child television viewing)
Number of subjects: 67
Study 22349644 — intervention group
Group type: COMPARATOR
Intervention: Control group (child safety)
Number of subjects: 67
Study 20110638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent solution with a lidocaine concentration of 400 mg/l
Number of subjects: 200
Study 20110638 — intervention group
Group type: COMPARATOR
Intervention: Tumescent solution with a lidocaine concentration of 500 mg/l
Number of subjects: 200
Study 18230379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 40
Study 18230379 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 40
Study 16397311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic-specific diabetes education programme
Number of subjects: 104
Study 16397311 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 104
Study 12894697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Border
Number of subjects: 24
Study 12894697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tielle and Allevyn Adhesive
Number of subjects: 24
Study 12894697 — intervention group
Group type: EXPERIMENTAL
Intervention: Duoderm Extra Thin, Biatain, and Versiva
Number of subjects: 24
Study 12894697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tielle and Allevyn
Number of subjects: 24
Study 10549449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid, 500 mg twice a day for 5 days
Number of subjects: 67
Study 10549449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 10549449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 67
Study 8652318 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation (initial i.v. boluses of 0.5 mg kg‐1 and fentanyl 1 microgram kg‐1, followed by an infusion of 50 micrograms kg‐1 min‐1)
Number of subjects: 36
Study 8390014 — intervention group
Group type: COMPARATOR
Intervention: Sequential immunosuppression with ALG, azathioprine, and steroids for 14 days (group A)
Number of subjects: 114
Study 8390014 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start to cyclosporin A after 2 days (group B)
Number of subjects: 114
Study 8390014 — intervention group
Group type: COMPARATOR
Intervention: Group A (14 days treatment)
Number of subjects: 114
Study 8390014 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2 days treatment)
Number of subjects: 114
Study 3323275 — intervention group
Group type: EXPERIMENTAL
Intervention: Diapers containing absorbent gelling material
Number of subjects: 0
Study 3323275 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cellulose core diapers
Number of subjects: 0
Study 3323275 — intervention group
Group type: COMPARATOR
Intervention: Cloth diapers
Number of subjects: 0
Study 3323275 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation of microorganisms
Number of subjects: 0
Study 3323275 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus isolation
Number of subjects: 0
Study 30286230 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram oxalate
Number of subjects: 125
Study 30286230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 30286230 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline QIDS-SR score
Number of subjects: 125
Study 28069072 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g × 4 and ibuprofen 400 mg × 4
Number of subjects: 556
Study 28069072 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g × 4 and placebo
Number of subjects: 556
Study 28069072 — intervention group
Group type: COMPARATOR
Intervention: Placebo and ibuprofen 400 mg × 4
Number of subjects: 556
Study 28069072 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 0.5 g × 4 and ibuprofen 200 mg
Number of subjects: 556
Study 28069072 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 556
Study 26003070 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP system
Number of subjects: 67
Study 26003070 — intervention group
Group type: COMPARATOR
Intervention: No PEP
Number of subjects: 67
Study 23572108 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-contact lenses (SCLs) with varying oxygen permeability
Number of subjects: 10
Study 23572108 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen permeability lenses
Number of subjects: 10
Study 23572108 — intervention group
Group type: COMPARATOR
Intervention: Classical data-interpretation procedure
Number of subjects: 10
Study 21654266 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 103
Study 21654266 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 20 mg/d
Number of subjects: 103
Study 21654266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 19133287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 14
Study 19133287 — intervention group
Group type: COMPARATOR
Intervention: Normal night's sleep
Number of subjects: 14
Study 16356696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-80 mg)
Number of subjects: 144
Study 15241721 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group 1 (TG1, n = 12): Plyometric training with rapid stretch contraction (0.4 m/s)
Number of subjects: 30
Study 15241721 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group 2 (TG2, n = 12): Plyometric training with slow stretch contraction (0.2 m/s)
Number of subjects: 30
Study 15241721 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG, n = 6)
Number of subjects: 30
Study 10932613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysplatin 60 mg/m2 and Etoposide 120 mg/m2 (Group A)
Number of subjects: 50
Study 10932613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysplatin 60 mg/m2 and Epirubicin 120 mg/m2 (Group B)
Number of subjects: 50
Study 10932613 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 120 mg/m2
Number of subjects: 50
Study 10932613 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 120 mg/m2
Number of subjects: 50
Study 8733686 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms G‐CSF/kg BW per day (group A)
Number of subjects: 67
Study 8733686 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms G‐CSF/kg BW per day (group B)
Number of subjects: 67
Study 1806953 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cannabis users
Number of subjects: 18
Study 1806953 — intervention group
Group type: COMPARATOR
Intervention: Nonuser controls
Number of subjects: 18
Study 6304870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 12
Study 6304870 — intervention group
Group type: COMPARATOR
Intervention: Control (non-fasting)
Number of subjects: 12
Study 31956722 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing embedded into usual physiotherapy care with a specifically designed app
Number of subjects: 0
Study 31956722 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 0
Study 31126564 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil massage
Number of subjects: 60
Study 31126564 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage (liquid paraffin)
Number of subjects: 60
Study 31126564 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 60
Study 28969978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome (Exparel)
Number of subjects: 0
Study 28969978 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride (Marcaine)
Number of subjects: 0
Study 26095339 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 7.5 mg
Number of subjects: 56
Study 26095339 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 6.0 mg
Number of subjects: 56
Study 23303417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) and Lithium (Li)
Number of subjects: 319
Study 23303417 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) and Lithium (Li)
Number of subjects: 319
Study 23303417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 21350201 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm none/mild (0%-33% decrease in arterial diameter)
Number of subjects: 381
Study 21350201 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm moderate (34%-66% decrease in arterial diameter)
Number of subjects: 381
Study 21350201 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm severe (≥67% decrease in arterial diameter)
Number of subjects: 381
Study 21350201 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 381
Study 19215547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular carbetocin (100 microg)
Number of subjects: 120
Study 19215547 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular syntometrine (0.5 mg ergometrine and 5IU oxytocin)
Number of subjects: 120
Study 17410120 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 50 mg
Number of subjects: 0
Study 17410120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoridazine 50 mg
Number of subjects: 0
Study 17410120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15173145 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing promotion and plain soap
Number of subjects: 3163
Study 15173145 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial soap
Number of subjects: 3163
Study 15173145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3163
Study 11692178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25-100 mg)
Number of subjects: 219
Study 11692178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 9137901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 86
Study 9137901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 7982251 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-ER (5 mg once daily, increased to 10 mg if needed)
Number of subjects: 277
Study 7982251 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS (30 mg once daily, increased to 60 or 90 mg if needed)
Number of subjects: 277
Study 7982251 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-ER
Number of subjects: 277
Study 7982251 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 277
Study 2972308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (1 mg)
Number of subjects: 9
Study 2972308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (40 mg)
Number of subjects: 9
Study 31065889 — intervention group
Group type: EXPERIMENTAL
Intervention: MoVo-LISA intervention (treatment as usual plus MoVo-LISA)
Number of subjects: 202
Study 31065889 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 202
Study 28483182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (two sessions, each lasting 20 minutes, administered one hour and three hours after attending the women's division)
Number of subjects: 120
Study 28483182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 120
Study 25617026 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccotherm®
Number of subjects: 60
Study 25617026 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeros®
Number of subjects: 60
Study 25617026 — intervention group
Group type: EXPERIMENTAL
Intervention: Marshmallow root
Number of subjects: 60
Study 25617026 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 23264399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/d)
Number of subjects: 20
Study 23264399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21215550 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 2 g
Number of subjects: 133
Study 21215550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 18623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation method based on compliance-type-specific treatment effect estimates
Number of subjects: 0
Study 18623608 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel mixture analysis using ML-EM estimation method
Number of subjects: 0
Study 16490288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated GPs
Number of subjects: 0
Study 16490288 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated GPs
Number of subjects: 0
Study 12592542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index
Number of subjects: 289